OXB Acquires Remaining Stake in US Subsidiary, Solidifying Its Position in the Viral Vector Manufacturing Market.

Oxford Biomedica Solutions LLC has acquired the remaining 10% stake in its US subsidiary, OXB US LLC, from Q32 Bio, Inc. This brings OXB's ownership to 100%, aligning with its global strategy and supporting long-term growth in the viral vector manufacturing market. The US facility has been integrated into OXB's network and offers lentiviral and AAV vector capabilities, supporting multiple new programs in the US.

Oxford Biomedica PLC (OXB) has completed the acquisition of the remaining 10% stake in its US subsidiary, OXB US LLC, from Q32 Bio, Inc. This brings OXB's ownership to 100%, aligning with its global strategy and supporting long-term growth in the viral vector manufacturing market [1]. The acquisition was finalized on June 23, 2025, following the exercise of a call option by OXB US Inc. on March 1, 2025 [2].

The US facility, originally established in 2022, offers lentiviral and adeno-associated virus (AAV) vector capabilities, spanning 96,000 square feet. It has been successfully integrated into OXB's global network, supporting the onboarding of multiple new programs in the US [3]. This acquisition strengthens OXB's position in a key market and helps meet growing demand for high-quality vector manufacturing, a critical enabler of the expanding cell and gene therapy market [3].

OXB's Chief Executive Officer, Frank Mathias, commented, "The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing - a critical enabler of the expanding cell and gene therapy market. Our presence in the US, alongside our existing sites in the UK and France, gives clients access to deep expertise across AAV and lentiviral-based therapies. Through OXB's network, we are able to support clients globally across all key vector types - from early-stage development through to commercialization" [3].

The acquisition of OXB US LLC aligns with OXB's mission to enable clients to deliver life-changing therapies to patients around the world. OXB's capabilities range from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise [3]. The company is headquartered in Oxford, UK, with development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford, MA, US.

Shares in Oxford BioMedica were down 3.0% at 311.50 pence in London at midday on Monday, June 23, 2025 [1].

References:
[1] https://www.lse.co.uk/news/oxford-biomedica-completes-purchase-of-last-10-stake-in-us-subsidiary-hsay62hpxbrke7d.html
[2] https://www.marketscreener.com/quote/stock/Q32-BIO-INC-42529124/news/OXB-US-Inc-completed-the-acquisition-of-remaining-10-of-OXB-US-LLC-from-Q32-Bio-Inc--50306496/
[3] https://www.investegate.co.uk/announcement/rns/oxford-biomedica--oxb/oxb-completes-acquisition-of-us-subsidiary/8941416